These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6519163)

  • 21. Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients.
    Wargin WA; Sawchuk RJ; McBride JW; McCoy HG; Rylander ML
    Eur J Drug Metab Pharmacokinet; 1982; 7(3):183-9. PubMed ID: 7173272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological determinants of propranolol disposition in man.
    Kornhauser DM; Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1978 Feb; 23(2):165-74. PubMed ID: 620476
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of portasystemic anastomoses in childhood on propranolol pharmacokinetics].
    Cario WR; Glende M; Lampe D; Buchali K; Bürger K; Grossmann P; Huth M; Rüstow B; Zimmermann HB
    Schweiz Med Wochenschr; 1981 Jul; 111(29):1088-93. PubMed ID: 7268362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of chlorpromazine on the disposition and beta-adrenergic blocking activity of propranolol in the dog.
    Bai SA; Abramson FP
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):333-49. PubMed ID: 6502474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade.
    Wilson TW; Firor WB; Johnson GE; Holmes GI; Tsianco MC; Huber PB; Davies RO
    Clin Pharmacol Ther; 1982 Dec; 32(6):676-85. PubMed ID: 7140133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relative bioavailability of a commercial propranolol hydrochloride tablet in man.
    Roscoe R; Cooper J; Wilson TW; Joshi NN; Midha KK
    Biopharm Drug Dispos; 1982; 3(2):105-14. PubMed ID: 7104460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Propranolol disposition in renal failure.
    Wood AJ; Vestal RE; Spannuth CL; Stone WJ; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1980 Dec; 10(6):561-6. PubMed ID: 7470370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet.
    Fagan TC; Walle T; Oexmann MJ; Walle UK; Bai SA; Gaffney TE
    Clin Pharmacol Ther; 1987 Apr; 41(4):402-6. PubMed ID: 3829577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of terodiline in human volunteers.
    Karlén B; Andersson KE; Ekman G; Strömberg S; Ulmsten U
    Eur J Clin Pharmacol; 1982; 23(3):267-70. PubMed ID: 7173296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Propranolol disposition in chronic liver disease: a physiological approach.
    Branch RA; Shand DG
    Clin Pharmacokinet; 1976; 1(4):264-79. PubMed ID: 797499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propranolol absorption in untreated coeliac disease.
    Sandle GI; Ward A; Rawlins MD; Record CO
    Clin Sci (Lond); 1982 Jul; 63(1):81-5. PubMed ID: 7083769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of propranolol and sotalol in hyperthyroidism.
    Aro A; Anttila M; Korhonen T; Sundquist H
    Eur J Clin Pharmacol; 1982; 21(5):373-7. PubMed ID: 7075642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of age on the hepatic clearance of propranolol in rats.
    Iwamoto K; Watanabe J; Araki K; Deguchi N; Sugiyama H
    J Pharm Pharmacol; 1985 Jul; 37(7):466-70. PubMed ID: 2863348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man.
    Cid E; Mella F; Lucchini L; Cárcamo M; Monasterio J
    Biopharm Drug Dispos; 1986; 7(6):559-66. PubMed ID: 3828485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of oral activated charcoal on propranolol pharmacokinetics following intravenous administration to rabbits.
    al-Meshal MA; el-Sayed YM; al-Angary AA; al-Dardiri MM
    J Clin Pharm Ther; 1993 Feb; 18(1):39-44. PubMed ID: 8473358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of propranolol isomers and their relationships with beta adrenoceptor blocking activity in rabbits administered with dl-propranolol.
    Kawashima K; Ishikawa H
    J Pharmacol Exp Ther; 1980 Jun; 213(3):628-31. PubMed ID: 6110769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.
    Evans GH; Shand DG
    Clin Pharmacol Ther; 1973; 14(4):494-500. PubMed ID: 4723256
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of route of administration and blood flow on hepatic drug elimination.
    Shand DG; Kornhauser DM; Wilkinson GR
    J Pharmacol Exp Ther; 1975 Dec; 195(3):424-32. PubMed ID: 1195129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.